Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Equillium ( (EQ) ) just unveiled an update.
On September 19, 2025, Equillium, Inc. announced the filing of a prospectus supplement with the SEC for the offer and sale of up to $75 million in common stock under an amended sales agreement with LifeSci Capital LLC. This move follows previous sales of shares that generated $0.96 million, indicating a strategic effort to raise capital and potentially expand its market presence.
The most recent analyst rating on (EQ) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Equillium stock, see the EQ Stock Forecast page.
Spark’s Take on EQ Stock
According to Spark, TipRanks’ AI Analyst, EQ is a Neutral.
Equillium’s overall score is driven by positive corporate events and strong technical momentum. However, financial performance and valuation concerns, including ongoing losses and operational inefficiencies, weigh down the score.
To see Spark’s full report on EQ stock, click here.
More about Equillium
Equillium, Inc. operates in the biotechnology industry, focusing on the development and commercialization of products aimed at treating severe autoimmune and inflammatory disorders.
Average Trading Volume: 8,034,178
Technical Sentiment Signal: Buy
Current Market Cap: $91.04M
See more insights into EQ stock on TipRanks’ Stock Analysis page.